Can a new drug turn the tide on Hard-to-Treat blood conditions?
NCT ID NCT07753148
First seen Aug 07, 2026 · Last updated Aug 07, 2026
Summary
This trial is testing an experimental drug called REGN17235 in people with two related blood conditions: clonal cytopenia of undetermined significance (CCUS) and low-risk myelodysplastic syndrome (MDS), both linked to a specific genetic change called an SF3B1 mutation. The main goals are to check the drug's safety, find the best dose, and see if it can improve blood cell counts. The study will also measure how the drug moves through the body and whether the immune system reacts to it.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- REGN17235, an experimental drug
- What this could lead to
- If successful, this could lead to a new treatment option that improves blood counts and reduces transfusion needs in people with certain blood disorders.
- What could go wrong
- This is an early-phase trial with a small number of participants, so the drug may not work as hoped or may cause unexpected side effects. The results will not be known until the trial is complete.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CLONAL CYTOPENIA OF UNDETERMINED SIGNIFICANCE (CCUS) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.